Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | GLA | P06280 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269309 | 1.00 | KDM4E (0.63) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL7061171 | 0.85 | MAPK8 (0.63) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL7067713 | 0.85 | MAPK8 (0.63) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL7061175 | 0.85 | MAPK8 (0.63) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL7061181 | 0.82 | NPC1 (0.64) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL21775874 | 0.81 | KDM4E (0.78) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL7066787 | 0.81 | NPC1 (0.63) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL18148785 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL18148863 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL18171904 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1HPGDL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | claimed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | claimed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | claimed |
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | disclosed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100546-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | KDM4E 3423/4885ALDH1A1 4036/4885HPGD 2042/4885 |
| US-20020061897-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | KDM4E 3423/4885ALDH1A1 4036/4885HPGD 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.